Sparc

SPARC completes enrollment in PROSEEK Global Phase 2 study of Parkinson's

PROSEEK, one of the largest phase-2 studies in early Parkinson's disease, encompassed 84 sites across the United States, Europe, and India

SBI Card, SPARC: Top stock picks by Vaishali Parekh of Prabhudas Lilladher

The stock of SBI Card has witnessed a decent correction from the peak of 1139 levels and has bottomed out near 920 levels

Two stocks that Vaishali Parekh of Prabhudas Lilladher is bullish on

The chart looks attractive for further upside movement in SPARC with the RSI indicator also showing a trend reversal

SPARC back in the black in Q1, reports profit of Rs 57 cr; stock jumps 14%

It's revenue from operations for the quarter under review came in at Rs 185.45 crore, clocking a growth of 970.73 per cent YoY from Rs17.32 crore reported in Q1FY20

SPARC slips 10% as USFDA rejects cancer drug application

The company has received a Complete Response Letter (CRL) from the USFDA for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension).

SPARC zooms 6% after US-based firm withdraws patent infringement complaint

In August this year, Abraxis Biosciences LLC had alleged that SPARC's filing of NDA or Taclantis injection is an act of infringement of the Orange Book listed patents for Abraxane.

SPARC's Sept quarter loss widens to Rs 63 cr from Rs 2.58 cr last year

Shares of SPARC were trading at Rs 146.7 apiece, up 2.34% on the BSE

SPARC falls 15% as phase III study of Baclofen GRS fails to meet end points

The stock dipped 15% to Rs 332 on BSE in early morning trade on back of heavy volumes

SPARC gets income tax demand notice for Rs 32.87 cr

The company is contesting the demand, which is for the assessment year 2013-14